{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T00:42:55Z","timestamp":1794876175461,"version":"4.9.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853800"],"award-info":[{"award-number":["853800"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["Mustart ANR-20-PAMR-0005"],"award-info":[{"award-number":["Mustart ANR-20-PAMR-0005"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010095","name":"R\u00e9gion Hauts-de-France","doi-asserted-by":"publisher","award":["2108838"],"award-info":[{"award-number":["2108838"]}],"id":[{"id":"10.13039\/501100010095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Ethionamide (Eto) and prothionamide (Pto) are second-line antibiotics used for tuberculosis (TB) treatment. Both are prodrugs whose antibacterial activity depends on bioactivation by oxidases in\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    , including the Baeyer-Villiger monooxygenase MymA. Through biophysical, genetic, and cellular assays, we show that the clinical candidate alpibectir (Alp, BVL-GSK098) binds the transcriptional regulator VirS, increasing MymA expression and potentiating Eto and Pto activity. Alpibectir also boosts the activity of the corresponding host-derived sulfoxide metabolites. We additionally show that alpibectir exhibits intrinsic antibacterial activity via overexpression of the\n                    <jats:italic>mymA<\/jats:italic>\n                    operon. The alpibectir\/Eto (AlpE) combination is rapidly bactericidal in vitro and in mice, lowers the frequency of spontaneous resistance of Eto, and remains active on Eto- and isoniazid-resistant strains, including isolates with\n                    <jats:italic>inhA<\/jats:italic>\n                    promoter mutations. Alpibectir was safe in a Phase 1 human clinical trial. Together with the potentiation data presented here, these findings highlight its potential to optimize TB chemotherapy by reducing Eto\/Pto doses, which can minimize dose-related side effects, enhancing adherence.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-71460-6","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:46:15Z","timestamp":1775573175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Alpibectir\u2013Ethionamide combination (AlpE) for the treatment of tuberculosis"],"prefix":"10.1038","volume":"17","author":[{"given":"Zainab","family":"Edoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Grosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Maitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosangela","family":"Frita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8846-5069","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Chauffour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Fournier Le Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5211-5796","authenticated-orcid":false,"given":"Alexandre","family":"Godmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Aubry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyne","family":"Bourotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7369-0626","authenticated-orcid":false,"given":"Rudy","family":"Antoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Tawk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Slupek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8961-1371","authenticated-orcid":false,"given":"Vincent","family":"Trebosc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Schellhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Dreneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Lociuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn E.","family":"Dale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2731-0327","authenticated-orcid":false,"given":"Fran\u00e7oise","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4464-9528","authenticated-orcid":false,"given":"Esther","family":"P\u00e9rez-Herr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2493-4118","authenticated-orcid":false,"given":"Alfonso","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Rebollo L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Ghidelli-Disse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lluis","family":"Ballell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4099-0438","authenticated-orcid":false,"given":"David","family":"Barros-Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5218-927X","authenticated-orcid":false,"given":"Vanessa","family":"Mathys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Soetaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Megalizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0234-7847","authenticated-orcid":false,"given":"Ren\u00e9","family":"Wintjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Gitzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2777-4538","authenticated-orcid":false,"given":"Benoit","family":"Deprez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Veziris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Modesto J.","family":"Remui\u00f1\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Willand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Pieren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0150-5241","authenticated-orcid":false,"given":"Alain R.","family":"Baulard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"71460_CR1","unstructured":"World Health Organization. Global Tuberculosis Report. (2024)."},{"key":"71460_CR2","unstructured":"World Health Organization. Global Tuberculosis Report. (2023)."},{"key":"71460_CR3","doi-asserted-by":"crossref","unstructured":"World Health Organization. WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment - Drug-Resistant Tuberculosis Treatment. (2021).","DOI":"10.30978\/TB2021-2-86"},{"key":"71460_CR4","unstructured":"World Health Organization. WHO Consolidated Guidelines on Tuberculosis. Module 5: Management of Tuberculosis in Children and Adolescents. Geneva: World Health Organization. (2022)."},{"key":"71460_CR5","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.tube.2015.09.007","volume":"97","author":"S Thee","year":"2016","unstructured":"Thee, S., Garcia-Prats, A. J., Donald, P. R., Hesseling, A. C. & Schaaf, H. S. A review of the use of ethionamide and prothionamide in childhood tuberculosis. Tuberculosis 97, 126\u2013136 (2016).","journal-title":"Tuberculosis"},{"key":"71460_CR6","doi-asserted-by":"publisher","first-page":"1901522","DOI":"10.1183\/13993003.01522-2019","volume":"54","author":"S Borisov","year":"2019","unstructured":"Borisov, S. et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur. Respiratory J. 54, 1901522 (2019).","journal-title":"Eur. Respiratory J."},{"key":"71460_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1084\/jem.20062100","volume":"204","author":"F Wang","year":"2007","unstructured":"Wang, F. et al. Mechanism of thioamide drug action against tuberculosis and leprosy. J. Exp. Med. 204, 73\u201378 (2007).","journal-title":"J. Exp. Med."},{"key":"71460_CR8","first-page":"227","volume":"263","author":"A Banerjee","year":"1994","unstructured":"Banerjee, A. et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science (1979) 263, 227\u2013230 (1994).","journal-title":"Science (1979)"},{"key":"71460_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1046\/j.1365-2958.2003.03809.x","volume":"51","author":"J Engohang-Ndong","year":"2004","unstructured":"Engohang-Ndong, J. et al. EthR, a repressor of the TetR\/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator. Mol. Microbiol. 51, 175\u2013188 (2004).","journal-title":"Mol. Microbiol."},{"key":"71460_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nm.1950","volume":"15","author":"N Willand","year":"2009","unstructured":"Willand, N. et al. Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat. Med. 15, 537\u2013544 (2009).","journal-title":"Nat. Med."},{"key":"71460_CR11","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1021\/jm200076a","volume":"54","author":"M Flipo","year":"2011","unstructured":"Flipo, M. et al. Ethionamide boosters: Synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors. J. Med. Chem. 54, 2994\u20133010 (2011).","journal-title":"J. Med. Chem."},{"key":"71460_CR12","doi-asserted-by":"publisher","first-page":"6391","DOI":"10.1021\/jm300377g","volume":"55","author":"M Flipo","year":"2012","unstructured":"Flipo, M. et al. Discovery of novel N -phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. J. Med. Chem. 55, 6391\u20136402 (2012).","journal-title":"J. Med. Chem."},{"key":"71460_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1021\/jm200825u","volume":"55","author":"M Flipo","year":"2012","unstructured":"Flipo, M. et al. Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors. J. Med. Chem. 55, 68\u201383 (2012).","journal-title":"J. Med. Chem."},{"key":"71460_CR14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1021\/acsinfecdis.9b00277","volume":"6","author":"B Villemagne","year":"2020","unstructured":"Villemagne, B. et al. Fragment-based optimized EthR inhibitors with in vivo ethionamide boosting activity. ACS Infect. Dis. 6, 366\u2013378 (2020).","journal-title":"ACS Infect. Dis."},{"key":"71460_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.molcel.2004.09.020","volume":"16","author":"F Fr\u00e9nois","year":"2004","unstructured":"Fr\u00e9nois, F., Engohang-Ndong, J., Locht, C., Baulard, A. R. & Villeret, V. Structure of EthR in a ligand bound conformation reveals therapeutic perspectives against tuberculosis. Mol. Cell 16, 301\u2013307 (2004).","journal-title":"Mol. Cell"},{"key":"71460_CR16","doi-asserted-by":"publisher","first-page":"9994","DOI":"10.1073\/pnas.0800663105","volume":"105","author":"W Weber","year":"2008","unstructured":"Weber, W. et al. A synthetic mammalian gene circuit reveals antituberculosis compounds. Proc. Natl. Acad. Sci. Usa 105, 9994 (2008).","journal-title":"Proc. Natl. Acad. Sci. Usa"},{"key":"71460_CR17","doi-asserted-by":"crossref","unstructured":"Willand, N., Flipo, M., Villemagne, B., Baulard, A. & Deprez, B. Recent advances in the design of inhibitors of mycobacterial transcriptional regulators to boost thioamides anti-tubercular activity and circumvent acquired-resistance. Ann. Rep. Med. Chem. 52, 131\u2013152 (2019).","DOI":"10.1016\/bs.armc.2019.06.003"},{"key":"71460_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejmech.2018.09.038","volume":"159","author":"M Prieri","year":"2018","unstructured":"Prieri, M. et al. Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis. Eur. J. Med. Chem. 159, 35\u201346 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"71460_CR19","doi-asserted-by":"crossref","unstructured":"Costa-Gouveia, J. et al. Combination therapy for tuberculosis treatment: Pulmonary administration of ethionamide and booster co-loaded nanoparticles. Sci. Rep. 7, 5390 (2017).","DOI":"10.1038\/s41598-017-05453-3"},{"key":"71460_CR20","first-page":"1206","volume":"355","author":"N Blondiaux","year":"2017","unstructured":"Blondiaux, N. et al. Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420. Science (1979) 355, 1206\u20131211 (2017).","journal-title":"Science (1979)"},{"key":"71460_CR21","doi-asserted-by":"crossref","unstructured":"Flipo, M. et al. Small-molecule SMARt751 hypersensitizes M. tuberculosis resistant to ethionamide by upregulating the mymA operon. Sci. Transl. Med. 14, eaaz6280 (2021).","DOI":"10.1126\/scitranslmed.aaz6280"},{"key":"71460_CR22","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1093\/jac\/dkae107","volume":"79","author":"M Pieren","year":"2024","unstructured":"Pieren, M. et al. First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug. J. Antimicrobial Chemother. 79, 1353\u20131361 (2024).","journal-title":"J. Antimicrobial Chemother."},{"key":"71460_CR23","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJMc2504287","volume":"394","author":"M Pieren","year":"2026","unstructured":"Pieren, M. et al. Revival of Ethionamide by Alpibectir. N. Engl. J. Med. 394, 818\u2013819 (2026).","journal-title":"N. Engl. J. Med."},{"key":"71460_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1146\/annurev-pathol-042120-032916","volume":"16","author":"RL Kinsella","year":"2021","unstructured":"Kinsella, R. L. et al. Perspectives and Advances in the Understanding of Tuberculosis. Annu. Rev. Pathol.: Mechanisms Dis. 16, 377\u2013408 (2021).","journal-title":"Annu. Rev. Pathol.: Mechanisms Dis."},{"key":"71460_CR25","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1021\/ac0262560","volume":"75","author":"A Thompson","year":"2003","unstructured":"Thompson, A. et al. Tandem Mass Tags: A Novel Quantification Strategy for Comparative Analysis of Complex Protein Mixtures by MS\/MS. Anal. Chem. 75, 1895\u20131904 (2003).","journal-title":"Anal. Chem."},{"key":"71460_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1177\/108705710100600609","volume":"6","author":"MW Pantoliano","year":"2001","unstructured":"Pantoliano, M. W. et al. High-Density Miniaturized Thermal Shift Assays as a General Strategy for Drug Discovery. SLAS Discov. 6, 429\u2013440 (2001).","journal-title":"SLAS Discov."},{"key":"71460_CR27","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.chembiol.2016.05.011","volume":"23","author":"SS Grant","year":"2016","unstructured":"Grant, S. S. et al. Baeyer-Villiger Monooxygenases EthA and MymA Are Required for Activation of Replicating and Non-replicating Mycobacterium tuberculosis Inhibitors. Cell Chem. Biol. 23, 666\u2013677 (2016).","journal-title":"Cell Chem. Biol."},{"key":"71460_CR28","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/jac\/dkp237","volume":"64","author":"IL Bergval","year":"2009","unstructured":"Bergval, I. L., Schuitema, A. R. J., Klatser, P. R. & Anthony, R. M. Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance. J. Antimicrobial Chemother. 64, 515 (2009).","journal-title":"J. Antimicrobial Chemother."},{"key":"71460_CR29","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1128\/AAC.38.4.773","volume":"38","author":"HE Takiff","year":"1994","unstructured":"Takiff, H. E. et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother. 38, 773\u2013780 (1994).","journal-title":"Antimicrob. Agents Chemother."},{"key":"71460_CR30","first-page":"1027","volume":"22","author":"J P\u00fctter","year":"1972","unstructured":"P\u00fctter, J. Bestimmung von Prothionamid und Athionamid sowie den entsprechenden Sulfoxiden im Blutplasma. Arzneim.-Forsch.\/Drug Res. 22, 1027\u20131031 (1972).","journal-title":"Arzneim.-Forsch.\/Drug Res."},{"key":"71460_CR31","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.taap.2008.09.017","volume":"233","author":"MC Henderson","year":"2008","unstructured":"Henderson, M. C., Siddens, L. K., Morr\u00e9, J. T., Krueger, S. K. & Williams, D. E. Metabolism of the Anti-Tuberculosis Drug Ethionamide by Mouse and Human FMO1, FMO2 and FMO3 and Mouse and Human Lung Microsomes. Toxicol. Appl. Pharmacol. 233, 420 (2008).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"71460_CR32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/jac\/13.3.267","volume":"13","author":"PJ Jenner","year":"1984","unstructured":"Jenner, P. J., Ellard, G. A., Gruer, P. J. K. & Aber, V. R. A comparison of the blood levels and urinary excretion of ethionamide and prothionamide in man. J. Antimicrobial Chemother. 13, 267\u2013277 (1984).","journal-title":"J. Antimicrobial Chemother."},{"key":"71460_CR33","doi-asserted-by":"publisher","first-page":"9677","DOI":"10.1073\/pnas.97.17.9677","volume":"97","author":"AE DeBarber","year":"2000","unstructured":"DeBarber, A. E., Mdluli, K., Bosman, M., Bekker, L. G. & Barry, C. E. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. Usa 97, 9677\u20139682 (2000).","journal-title":"Proc. Natl. Acad. Sci. Usa"},{"key":"71460_CR34","doi-asserted-by":"publisher","first-page":"12824","DOI":"10.1074\/jbc.M110751200","volume":"277","author":"TA Vannelli","year":"2002","unstructured":"Vannelli, T. A., Dykman, A. & Ortiz De Montellano, P. R. The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J. Biol. Chem. 277, 12824\u201312829 (2002).","journal-title":"J. Biol. Chem."},{"key":"71460_CR35","unstructured":"World Health Organization. Technical Manual for Drug Susceptibility Testing of Medicines Used in the Treatment of Tuberculosis. (2018)."},{"key":"71460_CR36","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1073\/pnas.0305634101","volume":"101","author":"AG Tsolaki","year":"2004","unstructured":"Tsolaki, A. G. et al. Functional and evolutionary genomics of Mycobacterium tuberculosis: Insights from genomic deletions in 100 strains. Proc. Natl. Acad. Sci. Usa 101, 4865\u20134870 (2004).","journal-title":"Proc. Natl. Acad. Sci. Usa"},{"key":"71460_CR37","doi-asserted-by":"crossref","unstructured":"Maitre, T. et al. Levofloxacin activity at increasing doses in a murine model of fluoroquinolone-susceptible and -resistant tuberculosis. Antimicrob. Agents Chemother. 68, e00583-24 (2024).","DOI":"10.1128\/aac.00583-24"},{"key":"71460_CR38","doi-asserted-by":"crossref","unstructured":"Nuermberger, E. L. et al. GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment. Antimicrob. Agents Chemother. 66, e00132-22 (2022).","DOI":"10.1128\/aac.00132-22"},{"key":"71460_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24067-x","volume":"8","author":"BC Mourik","year":"2018","unstructured":"Mourik, B. C. et al. Improving treatment outcome assessment in a mouse tuberculosis model. Sci. Rep. 8, 5714 (2018).","journal-title":"Sci. Rep."},{"key":"71460_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0378-1097(03)00648-7","volume":"227","author":"A Singh","year":"2003","unstructured":"Singh, A., Jain, S., Gupta, S., Das, T. & Tyagi, A. K. mymA operon of Mycobacterium tuberculosis: its regulation and importance in the cell envelope. FEMS Microbiol. Lett. 227, 53\u201363 (2003).","journal-title":"FEMS Microbiol. Lett."},{"key":"71460_CR41","unstructured":"Rieder, H. L. Interventions for Tuberculosis Control and Elimination. International Union Against Tuberculosis and Lung Disease (2002)."},{"key":"71460_CR42","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1164\/rccm.200210-1125OC","volume":"167","author":"A Jindani","year":"2003","unstructured":"Jindani, A., Dor\u00e9, C. J. & Mitchison, D. A. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. 167, 1348\u20131354 (2003).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"71460_CR43","unstructured":"World Health Organization. WHO Treatment Guidelines for Isoniazid-Resistant Tuberculosis: Supplement to the WHO Treatment Guidelines for Drug-Resistant Tuberculosis. (2018)."},{"key":"71460_CR44","doi-asserted-by":"crossref","unstructured":"Dean, A. S. et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. PLoS Med. 17, e1003008 (2020).","DOI":"10.1371\/journal.pmed.1003008"},{"key":"71460_CR45","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/cid\/cir406","volume":"53","author":"KR Jacobson","year":"2011","unstructured":"Jacobson, K. R. et al. Treatment Outcomes of Isoniazid-Resistant Tuberculosis Patients, Western Cape Province, South Africa. Clin. Infect. Dis. 53, 369\u2013372 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"71460_CR46","doi-asserted-by":"publisher","first-page":"812","DOI":"10.5588\/ijtld.11.0637","volume":"16","author":"M Gegia","year":"2012","unstructured":"Gegia, M., Cohen, T., Kalandadze, I., Vashakidze, L. & Furin, J. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. Int. J. Tuberculosis Lung Dis. 16, 812\u2013816 (2012).","journal-title":"Int. J. Tuberculosis Lung Dis."},{"key":"71460_CR47","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1473-3099(16)30407-8","volume":"17","author":"M Gegia","year":"2017","unstructured":"Gegia, M., Winters, N., Benedetti, A., van Soolingen, D. & Menzies, D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect. Dis. 17, 223\u2013234 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"71460_CR48","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1183\/13993003.00438-2016","volume":"48","author":"A Scardigli","year":"2016","unstructured":"Scardigli, A. et al. Efficacy and tolerability of ethionamide versus prothionamide: a systematic review. Eur. Respiratory J. 48, 946\u2013952 (2016).","journal-title":"Eur. Respiratory J."},{"key":"71460_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.2042-7158.1967.tb07986.x","volume":"19","author":"JP Johnston","year":"1967","unstructured":"Johnston, J. P., Kane, P. O. & Kibby, M. R. The metabolism of ethionamide and its sulphoxide. J. Pharm. Pharmacol. 19, 1\u20139 (1967).","journal-title":"J. Pharm. Pharmacol."},{"key":"71460_CR50","first-page":"411","volume":"17","author":"M Grunert","year":"1967","unstructured":"Grunert, M. & Iwainsky, H. Zum Stoffwechsel des Athionamides und seines Sulfoxydes im Makroorganismus. Arzneim.-Forsch.\/Drug Res. 17, 411\u2013415 (1967).","journal-title":"Arzneim.-Forsch.\/Drug Res."},{"key":"71460_CR51","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/978-1-4939-2450-9_24","volume":"1285","author":"V Delorme","year":"2015","unstructured":"Delorme, V., Song, O. R., Baulard, A. & Brodin, P. Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays. Methods Mol. Biol. 1285, 387\u2013411 (2015).","journal-title":"Methods Mol. Biol."},{"key":"71460_CR52","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1128\/AAC.03205-14","volume":"58","author":"S Sharma","year":"2014","unstructured":"Sharma, S. et al. Simple and Rapid Method To Determine Antimycobacterial Potency of Compounds by Using Autoluminescent Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 58, 5801\u20135808 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"71460_CR53","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/emmm.201201689","volume":"4","author":"RC Hartkoorn","year":"2012","unstructured":"Hartkoorn, R. C. et al. Towards a new tuberculosis drug: pyridomycin - nature\u2019s isoniazid. EMBO Mol. Med. 4, 1032\u20131042 (2012).","journal-title":"EMBO Mol. Med."},{"key":"71460_CR54","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nmeth996","volume":"4","author":"JC van Kessel","year":"2007","unstructured":"van Kessel, J. C. & Hatfull, G. F. Recombineering in Mycobacterium tuberculosis. Nat. Methods 4, 147\u2013152 (2007).","journal-title":"Nat. Methods"},{"key":"71460_CR55","doi-asserted-by":"publisher","first-page":"757","DOI":"10.15252\/msb.20145625","volume":"10","author":"CS Hughes","year":"2014","unstructured":"Hughes, C. S. et al. Ultrasensitive proteome analysis using paramagnetic bead technology. Mol. Syst. Biol. 10, 757 (2014).","journal-title":"Mol. Syst. Biol."},{"key":"71460_CR56","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1021\/acs.jproteome.7b00913","volume":"17","author":"S Moggridge","year":"2018","unstructured":"Moggridge, S., Sorensen, P. H., Morin, G. B. & Hughes, C. S. Extending the Compatibility of the SP3 Paramagnetic Bead Processing Approach for Proteomics. J. Proteome Res. 17, 1730\u20131740 (2018).","journal-title":"J. Proteome Res."},{"key":"71460_CR57","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0378-1119(01)00824-1","volume":"282","author":"S Schlatter","year":"2002","unstructured":"Schlatter, S., Rimann, M., Kelm, J. & Fussenegger, M. SAMY, a novel mammalian reporter gene derived from Bacillus stearothermophilus alpha-amylase. Gene 282, 19\u201331 (2002).","journal-title":"Gene"},{"key":"71460_CR58","doi-asserted-by":"publisher","first-page":"108090","DOI":"10.1016\/j.jsb.2024.108090","volume":"216","author":"C Grosse","year":"2024","unstructured":"Grosse, C. et al. Crystal structure of the Mycobacterium tuberculosis VirS regulator reveals its interaction with the lead compound SMARt751. J. Struct. Biol. 216, 108090 (2024).","journal-title":"J. Struct. Biol."},{"key":"71460_CR59","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1107\/S0021889897006766","volume":"30","author":"A Vagin","year":"1997","unstructured":"Vagin, A. & Teplyakov, A. MOLREP: an Automated Program for Molecular Replacement. J. Appl. Crystallogr. 30, 1022\u20131025 (1997).","journal-title":"J. Appl. Crystallogr."},{"key":"71460_CR60","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"71460_CR61","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/ci200227u","volume":"51","author":"RA Laskowski","year":"2011","unstructured":"Laskowski, R. A. & Swindells, M. B. LigPlot+: Multiple Ligand\u2013Protein Interaction Diagrams for Drug Discovery. J. Chem. Inf. Model. 51, 2778\u20132786 (2011).","journal-title":"J. Chem. Inf. Model."},{"key":"71460_CR62","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1128\/AAC.01824-10","volume":"55","author":"N Veziris","year":"2011","unstructured":"Veziris, N., Truffot, C., Mainardi, J.-L. & Jarlier, V. Activity of Carbapenems Combined with Clavulanate against Murine Tuberculosis. Antimicrob. Agents Chemother. 55, 2597\u20132600 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"71460_CR63","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10096-004-1109-5","volume":"23","author":"E Nuermberger","year":"2004","unstructured":"Nuermberger, E. & Grosset, J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur. J. Clin. Microbiol. Infect. Dis. 23, 243\u2013255 (2004).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71460-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71460-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71460-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:02:53Z","timestamp":1780534973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71460-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71460"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71460-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.B., V.T., B.S., A.D., L.H., C.K., S.L., G.E.D., F.J., M.G., and M.P. are current or former BioVersys employees and hold stocks or stock options in the company. Z.E and R.F. are former BioVersys employees. The Sorbonne Universit\u00e9 Team (A.C., L.F., Th.M., A.G., N.V., A.A.) has received a research grant from BioVersys for conducting preclinical studies on Alpibectir\/Ethionamide, and is involved in the Respiri-NTM IMI-AMR project in collaboration with BioVersys. T.W. and S.G.D. are current Cellzome GmbH (a GSK company) employees and hold stocks or stock options in GSK. D.B-A., M.J.R., A.M-L., and L.B. are current or former GSK employees and hold stocks or stock options in the company. M.J.R.L. is former GSK employee. N.W., B.D., M. J. R., E. P-H, and M.B. are listed as co-inventors on patent WO 2019\/034700 Al entitled \u201cNovel compounds.\u201d N.W. and A.R.B. are consultants for BioVersys. B.D. is paid as scientific co-director of Institut Pasteur de Lille. A.R.B. team and the research unit U1177 - Drugs and Molecules for Living Systems received research funding from BioVersys. The remaining authors have no competing interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4954"}}